Investigating genetic factors in heart failure with preserved ejection fraction
Official title: Genetic variation in xanthine oxidase and heart failure preserved ejection fraction
Funded at Birmingham VA Medical Center · NIH-10951524 · Data updated 2026-11-12
This study is looking at how certain genetic differences in a protein called xanthine oxidase might affect heart failure with preserved ejection fraction in people with high blood pressure, and it hopes to find new ways to help manage this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Birmingham VA Medical Center NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | October 1, 2023 |
| Project end | September 30, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01BX005996-02 |
| Project ID | NIH-10951524 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with hypertension and symptoms of heart failure, particularly those of African American descent.
✕Less likely to help
Patients with heart failure due to reduced ejection fraction or those without hypertension may not benefit from this research.
What this research studies
This research focuses on understanding how genetic variations in xanthine oxidase (XOR) may contribute to heart failure with preserved ejection fraction (HFpEF), particularly in patients with hypertension. The study aims to explore the role of XOR in heart function and its potential as a new treatment target. By examining the relationship between XOR activity and heart muscle cell function, the research seeks to identify innovative therapeutic strategies for managing HFpEF. Patients may be involved in assessments that help clarify the genetic factors influencing their heart condition.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients suffering from heart failure with preserved ejection fraction.
How similar studies have gone: Previous research has shown promising results in targeting xanthine oxidase for cardiovascular conditions, suggesting potential for success in this novel approach.
Where this research is happening
-
Birmingham VA Medical Center
Birmingham, United States Active
Researchers
- Principal investigator: Dell'italia, Louis J. — Birmingham VA Medical Center
- Study coordinator: Dell'italia, Louis J.
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.